Trademark: 87739250
Word
GRIFTATIN
Status
Dead
Status Code
606
Status Date
Monday, July 26, 2021
Serial Number
87739250
Mark Type
4000
Filing Date
Sunday, December 31, 2017
Published for Opposition
Tuesday, April 24, 2018
Abandoned Date
Monday, July 26, 2021

Trademark Owner History
Sentar Pharmaceuticals - Owner At Publication

Classifications
5 Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of orodispersable tablets and/or sublingual tablets that facilitate the delivery of pharmaceutical preparations; Nutraceuticals for use as a dietary supplement; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment of the cardiovascular system, the circulatory system, the digestive system, the excretory system, the endocrine system, the integumentary system, the exocrine system, the lymphatic system, the immune system, the muscular system, the nervous system, the renal system, the urinary system, the reproductive system, and/or the skeletal system; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Cardiovascular pharmaceuticals; Chemical preparations for pharmaceutical or medical purposes, namely, for treatment of the endocannabinoid; Human vaccine preparations; Oral vaccine preparations

Trademark Events
Jul 26, 2021
Abandonment Notice E-Mailed - No Use Statement Filed
Jul 26, 2021
Abandonment - No Use Statement Filed
Jan 5, 2021
Notice Of Approval Of Extension Request E-Mailed
Jan 4, 2021
Extension 5 Granted
Dec 8, 2020
Extension 5 Filed
Dec 21, 2020
Case Assigned To Intent To Use Paralegal
Dec 8, 2020
Teas Extension Received
Jun 10, 2020
Notice Of Approval Of Extension Request E-Mailed
Jun 8, 2020
Extension 4 Granted
Jun 8, 2020
Extension 4 Filed
Jun 8, 2020
Teas Extension Received
Oct 17, 2019
Notice Of Approval Of Extension Request E-Mailed
Oct 15, 2019
Extension 3 Granted
Oct 15, 2019
Extension 3 Filed
Oct 15, 2019
Teas Extension Received
May 22, 2019
Teas Change Of Correspondence Received
May 24, 2019
Notice Of Approval Of Extension Request E-Mailed
May 22, 2019
Extension 2 Granted
May 22, 2019
Extension 2 Filed
May 22, 2019
Teas Extension Received
Jan 17, 2019
Attorney/Dom.Rep.Revoked And/Or Appointed
Jan 17, 2019
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Dec 21, 2018
Notice Of Approval Of Extension Request E-Mailed
Dec 19, 2018
Extension 1 Granted
Dec 19, 2018
Extension 1 Filed
Dec 19, 2018
Teas Extension Received
Jun 19, 2018
Noa E-Mailed - Sou Required From Applicant
Apr 24, 2018
Official Gazette Publication Confirmation E-Mailed
Apr 24, 2018
Published For Opposition
Apr 4, 2018
Notification Of Notice Of Publication E-Mailed
Mar 22, 2018
Approved For Pub - Principal Register
Mar 22, 2018
Assigned To Examiner
Jan 16, 2018
New Application Office Supplied Data Entered In Tram
Jan 3, 2018
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24